Cheok Meyling H, Pottier Nicolas, Kager Leo, Evans William E
Jean-Pierre Aubert Research Center, INSERM U837, Genomics Core IRCL-IMPRT, Lille, France.
Semin Hematol. 2009 Jan;46(1):39-51. doi: 10.1053/j.seminhematol.2008.09.002.
Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%. This exemplary progress is largely due to the optimization of existing treatment modalities rather than the discovery of new antileukemic agents. However, despite these high cure rates, the annual number of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers. The aim of pharmacogenetics is to develop strategies to personalize treatment and tailor therapy to individual patients, with the goal of optimizing efficacy and safety through better understanding of human genome variability and its influence on drug response. In this review, we summarize recent pharmacogenomic studies related to the treatment of pediatric ALL. These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.
儿童急性淋巴细胞白血病（ALL）的治疗进展显著，从四十年前的致命疾病到目前治愈率超过80%。这一堪称典范的进展很大程度上归功于现有治疗方式的优化，而非新抗白血病药物的发现。然而，尽管治愈率很高，但初始治疗后白血病复发的儿童年数量仍高于大多数儿童癌症新发病例的数量。药物遗传学的目的是制定个性化治疗策略，为个体患者量身定制治疗方案，目标是通过更好地理解人类基因组变异性及其对药物反应的影响来优化疗效和安全性。在本综述中，我们总结了近期与儿童ALL治疗相关的药物基因组学研究。这些研究表明，以儿童白血病为范例，药物基因组学有望进一步推动人类癌症的治疗。
